 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- anti-CD19 CAR-T cell therapy / Wuhan Sian Medical Tech
Long-Term Follow-up of Humanized and Murine CD19 CAR-T Cell Therapy for B-Cell Malignancies (SDCC - Halls G-H) - Nov 3, 2023 - Abstract #ASH2023ASH_4411;
Results indicate that humanized CAR-T therapy showed better safety and durable efficacy, especially in patients with higher tumor burden in bone marrow. Moreover, it could overcome immunogenicity-induced CAR-T resistance, providing treatment options for patients
- || anti-CD19 CAR-T cell therapy / Wuhan Sian Medical Tech
New P1 trial: Humanized CD19 Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy in Treating Patients With B-cell Malignancies (clinicaltrials.gov) - Jul 4, 2019
P1, N=10, Recruiting, Sponsor: Wuhan Sian Medical Technology Co., Ltd
- ||| anti-CD19 CAR-T cell therapy / Wuhan Sian Medical Tech
Enrollment change: CD19 Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy in Treating Patients With B-cell Malignancies (clinicaltrials.gov) - Mar 4, 2019
P1/2, N=80, Recruiting, Sponsor: Wuhan Sian Medical Technology Co., Ltd
Moreover, it could overcome immunogenicity-induced CAR-T resistance, providing treatment options for patients N=50 --> 80
- ||| anti-CD19 CAR-T cell therapy / Wuhan Sian Medical Tech
Enrollment change: Anti-CD19 CAR-T Therapy Bridging to HSCT for CD19+ B-Cell Malignancies (clinicaltrials.gov) - Mar 1, 2019
P1/2, N=50, Recruiting, Sponsor: Wuhan Sian Medical Technology Co., Ltd
N=50 --> 80 N=30 --> 50
- | anti-CD19 CAR-T cell therapy / Wuhan Sian Medical Tech
Phase classification: CD19 Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy in Treating Patients With B-cell Malignancies (clinicaltrials.gov) - Nov 21, 2018
P1/2, N=50, Recruiting, Sponsor: Wuhan Sian Medical Technology Co., Ltd
N=30 --> 50 Phase classification: P1 --> P1/2
- | anti-CD19 CAR-T cell therapy / Wuhan Sian Medical Tech
Trial initiation date: Anti-CD19 CAR-T Therapy Bridging to HSCT for CD19+ B-Cell Malignancies (clinicaltrials.gov) - Nov 21, 2018
P1/2, N=30, Recruiting, Sponsor: Wuhan Sian Medical Technology Co., Ltd
Phase classification: P1 --> P1/2 Initiation date: Jan 2018 --> Apr 2016
- | anti-CD19 CAR-T cell therapy / Wuhan Sian Medical Tech
Phase classification, Trial initiation date: Anti-CD19 CAR-T Therapy Combine With HSCT to Treat MRD+ B-cell Malignancies (clinicaltrials.gov) - Nov 20, 2018
P1/2, N=20, Recruiting, Sponsor: Wuhan Sian Medical Technology Co., Ltd
Initiation date: Jan 2018 --> Apr 2016 Phase classification: P1 --> P1/2 | Initiation date: Jan 2018 --> May 2016
- | anti-CD19 CAR-T cell therapy / Wuhan Sian Medical Tech
New P1/2 trial: Anti-CD19 CAR-T Therapy Bridging to HSCT for CD19+ B-Cell Malignancies (clinicaltrials.gov) - Dec 8, 2017
P1/2, N=30, Recruiting, Sponsor: Wuhan Sian Medical Technology Co., Ltd
- | anti-CD19 CAR-T cell therapy / Wuhan Sian Medical Tech
New P1 trial: Anti-CD19 CAR-T Therapy Combine With HSCT to Treat MRD+ B-cell Malignancies (clinicaltrials.gov) - Dec 8, 2017
P1, N=20, Recruiting, Sponsor: Wuhan Sian Medical Technology Co., Ltd
- anti-CD19 CAR-T cell therapy / Wuhan Sian Medical Tech
Enrollment change: CD19 Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy in Treating Patients With B-cell Malignancies (clinicaltrials.gov) - Nov 29, 2017
P1, N=50, Recruiting, Sponsor: Wuhan Sian Medical Technology Co., Ltd
Phase classification: P1 --> P1/2 | Initiation date: Jan 2018 --> May 2016 N=20 --> 50
- anti-CD19 CAR-T cell therapy / Wuhan Sian Medical Tech
New P1 trial: CD19 Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy in Treating Patients With B-cell Malignancies (clinicaltrials.gov) - Nov 16, 2016
P1, N=20, Recruiting, Sponsor: Wuhan Sian Medical Technology Co., Ltd